Novel effect of carvedilol on Ca2+ movement in renal tubular cells

Biochemical Pharmacology

Volumn 64, Issue 12, 2002, Pages 1777-1784

  Liu, Chun Peng ^a,b,c   Chiang, Hung Ting ^a,b,c   Jan, Chung Ren ^a  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Calcium; Carvedilol; Fura 2; MDCK cells; Renal; Thapsigargin

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; CALCIUM ION; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CARVEDILOL; CYCLIC AMP; FURA 2; MANGANESE; PHOSPHOLIPASE C; PROTEIN KINASE C; RYANODINE; THAPSIGARGIN;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; EXTRACELLULAR CALCIUM; KIDNEY TUBULE CELL; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CALCIUM; CARBAZOLES; CELLS, CULTURED; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY TUBULES; PROPANOLAMINES; TIME FACTORS; VASODILATOR AGENTS;

EID: 0037114467     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01417-X     Document Type: Article

References (42)

1. Carlson W., Oberg K. Clinical pharmacology of carvedilol. J. Cardiovasc. Pharmacol. Ther. 4:1999;205-218.
2. Abshagen U. A new molecule with vasodilating and beta-adrenoceptor blocking properties. J. Cardiovasc. Pharmacol. 10:1987;S23-S32.
3. Neugebauer G., Akpan W., von Mollendorff E., Neubert P., Reiff K. Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Pharmacol. 10:1987;S85-S88.
4. Moe G. Carvedilol in the treatment of chronic heart failure. Expert Opin. Pharmacother. 2:2001;831-843.
5. Ohlstein E.H., Douglas S.A., Sung C.P., Yue T.L., Louden C., Arleth A., Poste G., Ruffolo R.R. Jr., Feuerstein G.Z. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc. Natl. Acad. Sci. U.S.A. 90:1993;6189-6193.
6. Bleske B.E., Gilbert E.M., Munger M.A. Carvedilol: therapeutic application and practice guidelines. Pharmacotherapy. 18:1998;729-737.
7. Frishman W.H. Carvedilol. N. Engl. J. Med. 339:1998;1759-1765.
8. Karle C.A., Kreye V.A., Thomas D., Rockl K., Kathofer S., Zhang W., Kiehn J. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc. Res. 49:2001;361-370.
9. Asbrink S., Zickert A., Bratt J., Gyllenhammar H., Palmblad J. No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions. Biochem. Pharmacol. 59:2000;1007-1013.
10. Dandona P., Karne R., Ghanim H., Hamouda W., Aljada A., Magsino C.H. Jr. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation. 101:2000;122-124.
11. Noguchi N., Nishino K., Niki E. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem. Pharmacol. 59:2000;1069-1076.
12. Kurosaki K., Ikeda U., Maeda Y., Shimada K. Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes. J. Mol. Cell Cardiol. 32:2000;333-339.
13. Dupont A.G. Carvedilol and the kidney. Clin. Invest. 70:1992;S127-S131.
14. Wong V.Y., Laping N.J., Nelson A.H., Contino L.C., Olson B.A., Gygielko E., Campbell W.G. Jr., Barone F., Brooks D.P. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Br. J. Pharmacol. 134:2001;977-984.
15. Rodriguez-Perez J.C., Losada A., Anabitarte A., Cabrera J., Llobet J., Palop L., Plaza C. Effects of the novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablated rats. J. Pharmacol. Exp. Ther. 283:1997;336-344.
16. Van den Branden C., Gabriels M., Vamecq J., Vanden Houte K., Verbeelen D. Carvedilol protects against glomerulosclerosis in rat remnant kidney without general changes in antioxidant enzyme status. A comparative study of two beta-blocking drugs, carvedilol and propanolol. Nephron. 77:1997;319-324.
17. Kumar K.V., Shifow A.A., Naidu M.U., Ratnakar K.S. Carvedilol: a beta blocker with antioxidant property protects against gentamicin-induced nephrotoxicity in rats. Life Sci. 66:2000;2603-2611.
18. Stanley A.J., Therapondos G., Helmy A., Hayes P.C. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J. Hepatol. 30:1999;479-484.
19. Fassbinder W., Quarder O., Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study. Int. J. Clin. Pract. 53:1999;519-522.
20. 2+ signals. J. Cell Sci. 114:2001;2213-2222.
21. Clapham D.E. Calcium signaling. Cell. 80:1995;259-268.
22. + antiporter interactions. Am. J. Physiol. 261:1991;C482-C489.
23. Jan C.-R., Ho C.M., Wu S.N., Tseng C.J. The phospholipase C inhibitor U73122 increases cytosolic calcium in MDCK cells by activating calcium influx and releasing stored calcium. Life Sci. 63:1998;895-908.
24. i rises in Madin-Darby canine kidney (MDCK) cells. J. Pharmacol. Exper. Ther. 292:2000;358-365.
25. 2+ signals in Madin-Darby canine kidney cells. Naunyn Schmiedebergs Arch. Pharmacol. 363:2001;16-20.
26. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
27. Merritt J.E., Jacob R., Hallam T.J. Use of manganese to discriminate between calcium influx and mobilization from internal stores in stimulated human neutrophils. J. Biol. Chem. 264:1989;1522-1527.
28. Thastrup O., Cullen P.J., Drobak B.K., Hanley M.R., Dawson A.P. Thapsigargin, a tumor promotor, discharges intracellular calcium stores by specific inhibition of the endoplasmic reticulum calcium ATPase. Proc. Natl. Acad. Sci. U.S.A. 87:1990;2466-2470.
29. Thompson A.K., Mostafapour S.P., Denlinger L.C., Bleasdale J.E., Fisher S.K. The aminosteroid U73122 inhibits muscarinic receptor sequestration and phosphoinositide hydrolysis in SK-N-SH neuroblastoma cells. J. Biol. Chem. 266:1991;23856-23862.
30. Kramer B.K., Ress K.M., Erley C.M., Risler T. Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure. Eur. J. Clin. Pharmacol. 43:1992;85-88.
31. Gehr T.W., Tenero D.M., Boyle D.A., Qian Y., Sica D.A., Shusterman N.H. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur. J. Clin. Pharmacol. 55:1999;269-277.
32. 2+ current in rabbit ventricular myocytes. Eur. J. Pharmacol. 376:1999;189-201.
33. Putney J.W. Jr. A model for receptor-regulated calcium entry. Cell Calcium. 7:1986;1-12.
34. 2+ mobilization in Madin-Darby canine kidney cells. Eur. J. Pharmacol. 355:1998;219-233.
35. 2+ spikes. Nature. 418:2002;93-96.
36. 2+ in ECV304 endothelial cells by agents which elevate cAMP. Cell Calcium. 22:1997;229-234.
37. Mamas M.A., Terrar D.A. Inotropic actions of protein kinase C activation by phorbol dibutyrate in guinea-pig isolated ventricular myocytes. Exp. Physiol. 86:2001;561-570.
38. 2+ mobilization in human neutrophils. Int. Immunopharmacol. 1:2001;1341-1349.
39. Pedrosa Ribeiro C.M., McKay R.R., Hosoki E., Bird G.S., Putney J.W. Jr. Effects of elevated cytoplasmic calcium and protein kinase C on endoplasmic reticulum structure and function in HEK293 cells. Cell Calcium. 27:2000;175-185.
40. 2+ entry in Madin-Darby canine kidney cells. Cell Signal. 12:2000;265-269.
41. Tinel H., Kinne-Saffran E., Kinne R.K. Calcium signalling during RVD of kidney cells. Cell Physiol. Biochem. 10:2000;297-302.
42. Edelstein C.L., Ling H., Schrier R.W. The nature of renal cell injury. Kidney Int. 51:1997;1341-1351.